Guardant Health

Youtube Subscribe

Open: 19.26 Close: 18.37 Change: -0.89

The stock market through the eyes of an AI: Guardant Health.

This document will help you to evaluate Guardant Health without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Guardant Health are: test, Guardant, cancer, Health, blood, screen, study, …

Concept Map

Semantic Network

Stock Summary

Guardant Health Inc. is a member of the Zacks.com (Strong Buy) list of Zacks. The consensus EPS estimate for the quarter has been revised 1.3%. Guardant Healthcare Inc has gained 4.83%.

Today's Summary

Guardant Healths Shield test was able to detect cancer with 83% sensitivity. Food and Drug Administration is expected to consider the Shield blood test for approval sometime this year. The maker of the test, Guardant health, anticipates an FDA decision.

Today's News

The first blood test to screen for colorectal cancer could be approved this year. The Food and Drug Administration is expected to consider the Shield blood test for approval sometime this year, according to Guardant Health. Guardant Healths Shield (TM) blood test for colorectal cancer screening for adults age 45-84 who are at average risk. Shield test was able to detect cancer with 83% sensitivity. Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. ECLIPSE is a prospective registrational study to evaluate the performance of Guardants blood test in detecting signs of CRC. A blood test for colon cancer performed well in a study, expanding options for screening. The maker of the test, Guardant Health, anticipates an FDA decision. Guardant Health (GH, $18.45) RSI Indicator left the oversold zone on March 06, 2024 Tickeron - Stocks. This is a signal that GHs price could be shifting from a downtrend to an uptrend. According to a study published Wednesday, March 13, 2024, in the New England Journal of Medicine, the test performed well, expanding screening options. Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine. The test has an accuracy rate for colon cancer detection similar to stool tests used for early detection. Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. The company mentioned in the press release is Guardant health, Inc. The forward-looking statements in this press release are based on information available to Guardant. Guardant Health announces positive results from pivotal study evaluating a blood test for the detection of colorectal cancer. The test is intended to be complementary to and not a replacement for current recommended screening methods. A blood test for colon cancer performed well in a study, expanding options for screening. The maker of the test, Guardant Health, anticipates an FDA decision.

Stock Profile

" Guardant Health Inc. is a member of the Zacks.com (Strong Buy) list of Zacks. The consensus EPS estimate for the quarter has been revised 1.3%. Guardant Health ( NASDAQ:GH – Get Free Report ) last announced its quarterly earnings data on Thursday, August 3rd. Guardant health had a negative return on equity of 427.89% and a negative net margin of 99.62% Guardant has a Bullish sentiment reading. Guardant Healthcare Inc has gained 4.83% while the S&P 500 has fallen -0.12% on the stock sell has FinerawdownloadRocket Blu DUPbangLearnemis � incons Guardant Health ( NASDAQ:GH – Get Free Report ) last posted its earnings results on Thursday, August 3rd. There are 117.69 M shares outstanding in Guardant Health Inc Registered Shs, which values the company at $3.45 B. Compared to the closing price on Tuesday 10/03/2023 on NAS of $28.79, this is a drop of 0.00%. The high in the last 52 weeks of Guardant health stock was 62.63. Guardant Health has a market cap of $3.31 billion. As of October 2023 the market cap is the worlds 3066th most valuable company by market cap according to our data. Guardant is the 30th most valued company in the world. Guardant Health stock climbs following piper sandler sandler upgrade (gh) Share of Guardant shares were up 7% in afternoon trading following an upgrade by Piper Sandler. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. Guardant has commercially launched Guardant360®, Guardant 360 CDx, and GuardantINFINITY™ tests for advanced-stage cancer patients, and  Guardant Reveal™ for early-stage. Guardant Health is a leading precision medicine company focused on helping conquer cancer globally. The Guardant health screening portfolio aims to address the needs of individuals eligible for cancer screening. Reimbursement Specialist, Payment Posting (Hybrid, Onsite or Remote Options) Reimbundation Specialist, Client Services (Regional Supervisor) Guardant Health   Stanford, CA Full Time Job Description We are looking for a full-time Client Services Supervisor. Guardant Health CEO Helmy Eltoukhy: CancerMoonshot dream for colorectal cancer is for all patients to have access to life-saving technologies like blood-based screening that can help identify cancers at their earliest stages Guardant Health hosted the WRP4LC at its headquarters to observe Lung Cancer Awareness Month. Guardant Health announces collaboration with Amgen to develop cancer-precision-oncology platform. The potential to target KRAS G12C represents a potentially major therapeutic advancement. Guardant Health CEO Helmy Eltoukhy: By 2030, #ColorectalCancer is projected to be the No. 1 cancer. GuardantINFINITY is a smart liquid biopsy that allows researchers to gain unprecedented insights."

Keywords

How much time have you spent trying to decide whether investing in Guardant Health? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Guardant Health are: test, Guardant, cancer, Health, blood, screen, study, and the most common words in the summary are: health, guardant, cancer, test, job, news, screen, . One of the sentences in the summary was: Food and Drug Administration is expected to consider the Shield blood test for approval sometime this year. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #health #guardant #cancer #test #job #news #screen.

Read more →

Youtube Subscribe

---